cells from FA-A patients, we could demonstrate for the first time that gene targeting in primary hematopoietic precursors from FA patients is feasible and compatible with the phenotypic correction of these clinically relevant cells.
No takes yet. Share an insight, caveat, or question.
Díez et al. (2017) studied this question.